MCMedicalCodingSoftware
J3357

J3357: Ustekinumab, for subcutaneous injection, 1 mg

HCPCSActiveBETOS O1E

J3357 is a HCPCS Level II code for ustekinumab, for subcutaneous injection, 1 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusE

Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

Medically Unlikely Edits: units per day

The most units of J3357 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
90 units
MAI 3: Date of Service Edit: Clinical · Clinical: Data
outpatient
90 units
MAI 3: Date of Service Edit: Clinical · Clinical: Data
DME supplier
0, never payable
MAI 3: Date of Service Edit: Clinical · CMS Policy

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.

The CMS record for J3357

Long descriptor
Ustekinumab, for subcutaneous injection, 1 mg

The official wording. This is what the code means.

Short descriptor
Ustekinumab sub cu inj, 1 mg

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2011

When CMS introduced the code.

BETOS
O1E

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
51: Other

Drugs.

Codes adjacent to J3357

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J3357 is not quite right, the correct code is very often within a few positions of it.

  • J3304Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
  • J3305Injection, trimetrexate glucuronate, per 25 mgterminated
  • J3310Injection, perphenazine, up to 5 mgterminated
  • J3315Injection, triptorelin pamoate, 3.75 mg
  • J3316Injection, triptorelin, extended-release, 3.75 mg
  • J3320Injection, spectinomycin dihydrochloride, up to 2 gmterminated
  • J3350Injection, urea, up to 40 gm
  • J3355Injection, urofollitropin, 75 iuterminated
  • J3358Ustekinumab, for intravenous injection, 1 mg
  • J3360Injection, diazepam, up to 5 mg
  • J3364Injection, urokinase, 5000 iu vialterminated
  • J3365Injection, iv, urokinase, 250,000 i.u. vialterminated
  • J3370Injection, vancomycin hcl, 500 mgterminated
  • J3371Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mgterminated
  • J3372Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mgterminated
  • J3373Injection, vancomycin hydrochloride, 10 mg
HCPCS Level II2026Q4-Oct· effective October 1, 2026